New Nordic Healthbrands AB (publ) (NNH) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of New Nordic Healthbrands AB (publ) SEK 27.50, price SEK 17.50, upside +57.1%, quality 62 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch New Nordic Healthbrands AB (publ) for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 11.90 – kr 102.73 · fair‑value band kr 19.27 – kr 34.72 · the kr 17.50 price screens below the kr 27.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow New Nordic Healthbrands AB (publ) in your weekly email
Every Wednesday you see whether New Nordic Healthbrands AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
New Nordic Healthbrands AB (publ) manufactures and sells dietary supplements, herbal remedies, and related personal care products in the Nordic countries, rest of Europe, North America, and internationally.
Show more
New Nordic Healthbrands AB (publ) manufactures and sells dietary supplements, herbal remedies, and related personal care products in the Nordic countries, rest of Europe, North America, and internationally. The company offers body care, dietary supplements, facial care, assortment, and natural magic trio products; hair volume series, dietary supplements, shampoo and conditioner, hair care, and range products; vitality products, such as vitamins and minerals, body, fish oil and omega-3, menopause, sleep and relaxation, men's health, and magnesium products; detox, digestion, and weight loss products. It sells its products under the NEW NORDIC brand through pharmacies, department stores, travel retailers, health stores, e-commerce, and direct to consumers. New Nordic Healthbrands AB (publ) was founded in 1990 and is headquartered in Malmö, Sweden.
Stock analysis
New Nordic Healthbrands AB (publ) (NNH) currently trades at kr 17.50, while our model-based Fair Value estimate is kr 27.50, implying the stock looks roughly 36.4% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 32.10 per share, and 20 of the 24 models we run sit above the kr 17.50 price.
Bear case: the Earnings-Based group reads lowest at kr 10.21, and 4 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: kr 19.27 (bear) to kr 34.72 (bull), the price of kr 17.50 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 62/100 (solid quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
New Nordic Healthbrands AB (publ) reported revenue of 576M SEK in FY2025 versus 515M SEK in FY2021, a compound +2.9%/yr. Reported net income was 8.2M SEK in FY2025, compounding −21.2%/yr from FY2021.
Key figures
Market cap 108M SEK (≈ $10.9M) · P/E ratio 40.7 · P/S ratio 0.58 · EPS (TTM) kr 0.4300 · Dividend yield 1.4% · Net margin 1.4% · Return on equity 2.7% · Return on assets (EBIT) 2.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −3% fair-value upside, at 57%, NNH screens cheaper than that median.
Fair Value models
Bear kr 19.27Fair Value kr 27.50Bull kr 34.72
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 0.1322 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Start year 2020 (pandemic). Over 10 years: +6.8% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−16.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.4%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17% vs −3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 3%
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +4.1% a year for the price.
Compare New Nordic Healthbrands AB (publ) with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 666 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score62 · Above median
Fair Value upside+59% · Top 25%
Profitability
Return on equity (TTM)3% · Below median
Return on assets2% · Below median
Net margin (TTM)0% · Bottom 25%
Operating margin (TTM)−1% · Bottom 25%
Growth and dividend
Revenue growth−8% · Bottom 25%
Dividend yield (TTM)1.4% · Bottom 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "New Nordic Healthbrands AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/NNH
Frequently asked questions
Is New Nordic Healthbrands AB (publ) (NNH) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 27.50 versus a price of kr 17.50, about +57% upside (undervalued).
What is the fair value of NNH?
Our model-based fair value for New Nordic Healthbrands AB (publ) is kr 27.50 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 17.50.
What is the quality score of NNH?
New Nordic Healthbrands AB (publ) has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for New Nordic Healthbrands AB (publ) (NNH)?
Our model-based price target is the fair value of kr 27.50 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario kr 19.27, optimistic scenario kr 34.72. It is a calculation from audited fundamentals, not an analyst target.
What is the New Nordic Healthbrands AB (publ) stock forecast for 2026?
Our models put fair value at kr 27.50, about +57% upside versus a price of kr 17.50 (undervalued). Cautious scenario kr 19.27, optimistic scenario kr 34.72. The calculation is refreshed regularly with new filings.
What is the revenue of New Nordic Healthbrands AB (publ) (NNH)?
New Nordic Healthbrands AB (publ) reported trailing-twelve-month revenue of about 565M SEK (latest available figure, as of Sep 24, 2026).
Does New Nordic Healthbrands AB (publ) pay a dividend?
New Nordic Healthbrands AB (publ) currently shows a dividend yield of about 1.43% relative to its recent price (as of Sep 24, 2026).
What growth is priced into New Nordic Healthbrands AB (publ) (NNH)?
For today's price to be fair in a discounted-cash-flow model, New Nordic Healthbrands AB (publ) would have to grow free cash flow by +6.1 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of NNH use?
Our models discount New Nordic Healthbrands AB (publ) at 9.6 %: a base by market capitalisation (nano), damped by beta 1.04, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For New Nordic Healthbrands AB (publ) that is +6.1 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has New Nordic Healthbrands AB (publ) (NNH) delivered so far?
Over the past 5 years revenue at New Nordic Healthbrands AB (publ) grew +5.1 % a year. The price currently implies +6.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of New Nordic Healthbrands AB (publ) (NNH) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into New Nordic Healthbrands AB (publ) (+6.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of New Nordic Healthbrands AB (publ) (NNH)?
The free-cash-flow yield on the price is 6.99 %: that much free cash flow New Nordic Healthbrands AB (publ) produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of New Nordic Healthbrands AB (publ) (NNH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For New Nordic Healthbrands AB (publ) it is kr 27.50 per share (as of Sep 24, 2026), against a price of kr 17.50. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is New Nordic Healthbrands AB (publ) stock overvalued or undervalued in 2026?
As of Sep 24, 2026, NNH trades below its calculated fair value: price kr 17.50, fair value kr 27.50, a gap of about +57% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NNH?
No. The price is what the market pays today (kr 17.50); the fair value is what the company's own numbers justify (kr 27.50). For New Nordic Healthbrands AB (publ) the two are kr 10.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is New Nordic Healthbrands AB (publ) worth?
The market values New Nordic Healthbrands AB (publ) at about 108M SEK (market capitalisation, as of Sep 24, 2026). Per share that is kr 17.50; our models calculate a fair value of kr 27.50 per share.
What do the bullish and bearish scenarios say about NNH?
Our models span a range for New Nordic Healthbrands AB (publ): cautious scenario kr 19.27, base kr 27.50, optimistic kr 34.72 per share (as of Sep 24, 2026, price kr 17.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NNH?
New Nordic Healthbrands AB (publ) trades at a price-to-earnings ratio of 40.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 27.50 is built from several models across several years. Other multiples: P/B 1.0, P/S 0.2, EV/EBITDA 8.9.
How solid is the balance sheet of New Nordic Healthbrands AB (publ) (NNH)?
Balance-sheet figures for New Nordic Healthbrands AB (publ) (as of Sep 24, 2026): return on equity 2.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is NNH from its 52-week high?
New Nordic Healthbrands AB (publ) trades at kr 17.50, about 29% below its 52-week high of kr 24.70 and 47% above the low of kr 11.90 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 27.50 is for.
Which stocks are comparable to New Nordic Healthbrands AB (publ)?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, The Kraft Heinz Company, Foshan Haitian Flavouring and Food Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is New Nordic Healthbrands AB (publ) stock attractive at the current price?
The data as of Sep 24, 2026: price kr 17.50, calculated fair value kr 27.50 (+57%), Quality Score 62/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NNH calculated?
We run New Nordic Healthbrands AB (publ) through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 27.50, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. New Nordic Healthbrands AB (publ) currently trades 57 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of New Nordic Healthbrands AB (publ) (NNH)?
The closing price on Sep 24, 2026 was kr 17.50. Our model-based fair value is kr 27.50, about +57% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with New Nordic Healthbrands AB (publ) right now?
The price is below even our cautious bear case (kr 19.27). The market is more pessimistic than our downside scenario. Solid quality (62/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (kr 19.27 to kr 34.72) leaves room in how you read the outcome.
Key figures of New Nordic Healthbrands AB (publ)
How large is the market capitalisation of New Nordic Healthbrands AB (publ) (NNH)?
The market capitalisation of New Nordic Healthbrands AB (publ) is 108M SEK (≈ $10.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of New Nordic Healthbrands AB (publ) (NNH)?
The price-to-sales ratio of New Nordic Healthbrands AB (publ) is 0.58 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of New Nordic Healthbrands AB (publ) (NNH)?
Earnings per share at New Nordic Healthbrands AB (publ) are kr 0.4300 (price ÷ EPS = P/E 40.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of New Nordic Healthbrands AB (publ) (NNH)?
The dividend yield of New Nordic Healthbrands AB (publ) is 1.4% (payout 58.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of New Nordic Healthbrands AB (publ) (NNH)?
The net margin of New Nordic Healthbrands AB (publ) is 1.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of New Nordic Healthbrands AB (publ) (NNH)?
The return on equity (ROE) of New Nordic Healthbrands AB (publ) is 2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of New Nordic Healthbrands AB (publ) (NNH)?
On an EBIT basis the return on assets of New Nordic Healthbrands AB (publ) is 2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of New Nordic Healthbrands AB (publ) (NNH)?
The operating margin of New Nordic Healthbrands AB (publ) is −1.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at New Nordic Healthbrands AB (publ) (NNH)?
Revenue at New Nordic Healthbrands AB (publ) is growing −7.9% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at New Nordic Healthbrands AB (publ) (NNH)?
Earnings per share at New Nordic Healthbrands AB (publ) are growing +5.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does New Nordic Healthbrands AB (publ) (NNH) carry?
The net debt of New Nordic Healthbrands AB (publ) is 19.3M SEK (fiscal year 2025, ≈ 2.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch New Nordic Healthbrands AB (publ) in the live analysis
One click puts New Nordic Healthbrands AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
